Chronic hepatitis C virus (HCV) infection is now the leading cause of hepatocellular carcinoma (HCC), a highly lethal cancer with rapidly increasing incidence in the U.S. How HCV causes liver cancer is not well understood because of the lack of a small animal model for HCV pathogenesis. The overarching goal of this interdisciplinary, multi-PI project is to refine a recently developed humanized mouse model of hepatitis C (the AFC8-hu mouse) that possesses both a chimeric human liver and a functioning human immune system, and to use this model to elucidate viral mechanisms of carcinogenesis responsible for HCV-associated HCC. AFC8- hu mice engrafted with CD34+ human hematopoietic stem cells and EpCAM+ human hepatoblasts and hepatic stem cells achieve ~18% hepatic chimerism, are permissive for HCV infection, and develop a human HCV- specific T cell response with hepatic inflammation when infected with HCV. Remarkably, HCV infection of these mice results in significant hepatic fibrosis and evidence of oxidative DNA damage - hallmarks of chronic hepatitis C in human patients. Three interrelated specific aims are proposed to refine this model and to apply it to the study of the mechanisms of carcinogenesis responsible for HCV-associated HCC.
Aim 1 focuses on optimizing protocols to enhance hepatic chimerism in AFC8-hu mice, and to infect AFC8-hu mice with genotype 1a HCVcc produced in cell culture from recombinant DNA, thereby providing a system supporting reverse molecular viral genetics studies of HCV-mediated carcinogenesis.
In Aim 2, p53 will be inactivated in human hepatoblasts prior to transplantation into AFC8 mice to provide for accelerated development of human liver cancer in HCV-infected mice, and to facilitate discovery of novel determinants of HCV-mediated hepatocarcinogenesis.
Aim 3 will utilize a reverse molecular genetics strategy to test the hypothesis that the disruption of critical tumor suppressor function by HCV promotes cancer in the genotoxic environment of immune-mediated hepatic inflammation and oxidative stress, and to specifically assess the role played by the targeted destruction of the retinoblastoma protein by HCV and sequestration of the tumor suppressor DDX3 by HCV core protein. Further development of the AFC8-hu mouse model, coupled with the use of infectious genotype 1a H77S virus produced from recombinant cDNA, will provide a robust and completely unique experimental system in which the complex interplay of direct and indirect mechanisms of carcinogenesis can be elucidated. The results of these studies will add significantly to current understanding of how HCV infection leads to the development of HCC, and advance the development and evaluation of new preventative and therapeutic strategies to lessen the considerable burden of morbidity and mortality imposed by liver cancer in patients with chronic hepatitis C.

Public Health Relevance

Chronic hepatitis C virus (HCV) infection is now the leading cause of hepatocellular carcinoma (HCC) in the U.S., but how it causes liver cancer is not well understood because of the lack of a small animal model for hepatitis C. The goal of this project is to refine a recently developed, immunocompetent humanized mouse model (the AFC8-hu mouse) that develops a human immune response to HCV and liver inflammation when infected with HCV. Coupling this novel mouse model with reverse molecular viral genetics will provide a robust and unique experimental system in which mechanisms of carcinogenesis will be elucidated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA164029-02
Application #
8464678
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
2012-05-01
Project End
2017-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
2
Fiscal Year
2013
Total Cost
$442,453
Indirect Cost
$143,498
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Li, You; Masaki, Takahiro; Shimakami, Tetsuro et al. (2014) hnRNP L and NF90 interact with hepatitis C virus 5'-terminal untranslated RNA and promote efficient replication. J Virol 88:7199-209
Li, Feng; Cowley, Dale O; Banner, Debra et al. (2014) Efficient genetic manipulation of the NOD-Rag1-/-IL2RgammaC-null mouse by combining in vitro fertilization and CRISPR/Cas9 technology. Sci Rep 4:5290
Rusyn, Ivan; Lemon, Stanley M (2014) Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies? Cancer Lett 345:210-5
Yi, MinKyung; Hu, Fengyu; Joyce, Michael et al. (2014) Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J Virol 88:3678-94
Cheng, Liang; Du, Xuexiang; Wang, Zheng et al. (2014) Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. J Hepatol 61:1297-303
Jabara, Cassandra B; Hu, Fengyu; Mollan, Katie R et al. (2014) Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection. Antimicrob Agents Chemother 58:6079-92
Bility, Moses T; Curtis, Anthony; Su, Lishan (2014) A chimeric mouse model to study immunopathogenesis of HCV infection. Methods Mol Biol 1213:379-88
Yamane, Daisuke; McGivern, David R; Wauthier, Eliane et al. (2014) Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med 20:927-35
Spaniel, Carolyn; Honda, Masao; Selitsky, Sara R et al. (2013) microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS One 8:e76867
Li, You; Masaki, Takahiro; Lemon, Stanley M (2013) miR-122 and the Hepatitis C RNA genome: more than just stability. RNA Biol 10:919-23

Showing the most recent 10 out of 11 publications